Phase 1
Completed N=30
This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
Healthy
Source: ClinicalTrials.gov NCT03629054 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcomePrimary: Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 2134.53; 2125.57 nanomole*hour/litre (nmol*h/L) — p=<0.0001
Summary
The primary objective of this trial is to establish the bioequivalence of two empagliflozin/linagliptin/metformin extended release (XR) fixed dose combination (FDC) tablets (Test, T) compared with the same doses of the individual components given in separate tablets (Reference, R) when administered together after a high-fat, high-calorie meal.
The assessment of safety and tolerability will be the secondary objective of this trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) |
2134.53; 2125.57 | <0.0001 sig |
| PRIMARY Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) |
21687.12; 22748.21 | <0.0001 sig |
| PRIMARY Area Under the Concentration-time Curve of the Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (h) (AUC0-72) |
270.19; 269.77 | <0.0001 sig |
| PRIMARY Maximum Measured Concentration of the Empagliflozin in Plasma (Cmax) |
209.67; 226.50 | 0.0029 sig |
| PRIMARY Maximum Measured Concentration of the Linagliptin in Plasma (Cmax) |
7.02; 7.21 | 0.0001 sig |
| PRIMARY Maximum Measured Concentration of the Metformin in Plasma (Cmax) |
1853.03; 1767.69 | <0.0001 sig |
| SECONDARY Area Under the Concentration-time Curve of the Empagliflozin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) |
2182.26; 2166.54 | <0.0001 sig |
| SECONDARY Area Under the Concentration-time Curve of the Linagliptinin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) |
471.40; 455.13 | <0.0001 sig |
| SECONDARY Area Under the Concentration-time Curve of the Metformin Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) |
22288.72; 23280.48 | <0.0001 sig |
| SECONDARY Percentage of Patients With Drug-related Adverse Events (AEs) |
7; 6 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy male or female subjects according to the assessment of the investigator, based on a complete medical history including a physical examination, vital signs (Blood pressure (BP), Pulse rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests
- Age of 18 to 55 years (incl.)
- Body mass index (BMI) of 18.5 to 29.9 kg/m2 (incl.)
- Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation
- Female subjects of childbearing potential willing to use adequate contraception.
- Further inclusion criteria apply
Exclusion criteria
- Any finding in the medical examination (including Blood pressure (BP), Pulse rate (PR) or Electrocardiogram (ECG)) is deviating from normal and judged as clinically relevant by the investigator
- Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm)
- Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
- Any evidence of a concomitant disease judged as clinically relevant by the investigator
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
- Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
- Further exclusion criteria apply
Data sourced from ClinicalTrials.gov (NCT03629054). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.